AGA Nanotech

About AGA Nanotech

At AGA Nanotech, we want to rewrite the narrative around Antimicrobial Resistance (AMR). If antibiotics give rise to resistance, then why not use something that doesn’t? We developed Battlestar™, a revolutionary non-antibiotic antimicrobial technology platform. Unlike antibiotics, Battlestar targets multiple cellular pathways, preventing resistance while combating infections. It safely and stably delivers oxidative biocides, offering broad-spectrum antimicrobial and antibiofilm activity while supporting healing. Battlestar’s Unique Features Include: • Broad-spectrum activity: Effectively targets bacteria, viruses, fungi, and biofilms, providing robust antimicrobial and antibiofilm action. • Tissue-friendly technology: Encapsulation in PLGA minimises cytotoxicity while releasing healing agents like lactate to support tissue regeneration. • Sustained release: Microsphere technology ensures controlled antimicrobial delivery directly at the site of infection, reducing the need for frequent dosing, enhancing patient comfort, and optimizing clinical resources. • Biocompatibility: Decomposes into water, oxygen, lactic acid, and glycolic acid—naturally processed by the body to create an environment that supports healing. Battlestar is more than a technology; it’s a solution to AMR, designed to transform infection management across multiple healthcare sectors—including wound care, biofilm-associated tumours, urinary tract infections, and osteomyelitis—while preserving antibiotics, protecting patients, and preventing resistance.

View contact profiles from AGA Nanotech